{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:56:34Z","timestamp":1792245394759,"version":"4.4.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.trecan.2024.04.004","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T07:56:31Z","timestamp":1717487791000},"page":"643-654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer"],"prefix":"10.1016","volume":"10","author":[{"given":"Chris","family":"Abbosh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6631-9626","authenticated-orcid":false,"given":"Darren","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J.","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4521-8199","authenticated-orcid":false,"given":"Davina","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5598-7752","authenticated-orcid":false,"given":"James R.M.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2070-2547","authenticated-orcid":false,"given":"Leora","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge S.","family":"Reis-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4299-3018","authenticated-orcid":false,"given":"Charles","family":"Swanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2024.04.004_bb0005","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41571-023-00794-7","article-title":"Immune-checkpoint inhibition for resectable non-small-cell lung cancer \u2013 opportunities and challenges","volume":"20","author":"Mountzios","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.04.004_bb0010","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abg7836","article-title":"A reservoir of stem-like CD8(+) T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response","volume":"6","author":"Connolly","year":"2021","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.trecan.2024.04.004_bb0015","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124507","article-title":"Tumor-draining lymph nodes are pivotal in PD-1\/PD-L1 checkpoint therapy","volume":"3","author":"Fransen","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.trecan.2024.04.004_bb0020","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1038\/s41467-022-31941-w","article-title":"Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC","volume":"13","author":"Saddawi-Konefka","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2024.04.004_bb0025","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40425-018-0398-7","article-title":"Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity","volume":"6","author":"Bakos","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2024.04.004_bb0030","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41571-019-0319-9","article-title":"Harnessing cancer immunotherapy during the unexploited immediate perioperative period","volume":"17","author":"Matzner","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.04.004_bb0035","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2024.04.004_bb0040","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4143\/crt.2022.1026","article-title":"Clinical circulating tumor DNA testing for precision oncology","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.trecan.2024.04.004_bb0045","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s40291-021-00559-x","article-title":"Commercial ctDNA assays for minimal residual disease detection of solid tumors","volume":"25","author":"Chen","year":"2021","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.trecan.2024.04.004_bb0050","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.21037\/jtd.2019.07.43","article-title":"Validation of the 8th edition of the TNM staging system in 3,950 patients with surgically resected non-small cell lung cancer","volume":"11","author":"Yun","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.trecan.2024.04.004_bb0055","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jtho.2019.11.030","article-title":"Validation of the eighth edition TNM lung cancer staging system","volume":"15","author":"Hwang","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.trecan.2024.04.004_bb0060","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","article-title":"Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA","volume":"616","author":"Abbosh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2024.04.004_bb0065","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41586-020-2140-0","article-title":"Integrating genomic features for non-invasive early lung cancer detection","volume":"580","author":"Chabon","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2024.04.004_bb0070","doi-asserted-by":"crossref","first-page":"S1294","DOI":"10.1016\/j.annonc.2023.10.049","article-title":"LBA55. An ultra-sensitive and specific ctDNA assay provides novel pre-operative disease stratification in early stage lung cancer","volume":"34","author":"Black","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2024.04.004_bb0075","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1158\/1078-0432.CCR-21-3044","article-title":"Perioperative ctDNA-based molecular residual disease detection for non-small cell lung cancer: a prospective multicenter cohort study (LUNGCA-1)","volume":"28","author":"Xia","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2024.04.004_bb0080","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2024.04.004_bb0085","doi-asserted-by":"crossref","first-page":"S1300","DOI":"10.1016\/j.annonc.2023.10.055","article-title":"LBA59. Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase 3 AEGEAN trial","volume":"34","author":"Reck","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2024.04.004_bb0090","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1158\/2159-8290.CD-21-0634","article-title":"Detecting liquid remnants of solid tumors: circulating tumor DNA Minimal residual disease","volume":"11","author":"Moding","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2024.04.004_bb0095","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1200\/JCO.21.02660","article-title":"Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non-small-cell lung cancer (NADIM phase II trial)","volume":"40","author":"Provencio","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.04.004_bb0100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS6606","article-title":"NHS-Galleri trial design: equitable study recruitment tactics for targeted population-level screening with a multi-cancer early detection (MCED) test","volume":"40","author":"Swanton","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.04.004_bb0105","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.3390\/cancers12113371","article-title":"Promising therapy in lung cancer: spotlight on aurora kinases","volume":"12","author":"Galetta","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.trecan.2024.04.004_bb0110","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nature11935","article-title":"Replication stress links structural and numerical cancer chromosomal instability","volume":"494","author":"Burrell","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2024.04.004_bb0115","doi-asserted-by":"crossref","first-page":"5806","DOI":"10.1158\/1078-0432.CCR-12-0857","article-title":"Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome","volume":"18","author":"Wang","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2024.04.004_bb0120","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/bjc.2014.402","article-title":"Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role","volume":"111","author":"Warth","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.trecan.2024.04.004_bb0125","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12931-018-0843-7","article-title":"Augmented expression of Ki-67 is correlated with clinicopathological characteristics and prognosis for lung cancer patients: an up-dated systematic review and meta-analysis with 108 studies and 14,732 patients","volume":"19","author":"Wei","year":"2018","journal-title":"Respir. Res."},{"key":"10.1016\/j.trecan.2024.04.004_bb0130","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.cell.2018.08.027","article-title":"The multifaceted role of chromosomal instability in cancer and Its microenvironment","volume":"174","author":"Bakhoum","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2024.04.004_bb0135","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.ccell.2023.04.008","article-title":"Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy","volume":"41","author":"Magbanua","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2024.04.004_bb0140","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.ccell.2023.08.010","article-title":"Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer","volume":"41","author":"Chen","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2024.04.004_bb0145","doi-asserted-by":"crossref","first-page":"200","DOI":"10.18632\/oncotarget.28565","article-title":"Analytical validation of NeXT Personal\u00ae, an ultra-sensitive personalized circulating tumor DNA assay","volume":"15","author":"Northcott","year":"2024","journal-title":"Oncotarget"},{"key":"10.1016\/j.trecan.2024.04.004_bb0150","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2024.04.004_bb0155","doi-asserted-by":"crossref","first-page":"CT005","DOI":"10.1158\/1538-7445.AM2023-CT005","article-title":"AEGEAN: a phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC","volume":"83","author":"Heymach","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2024.04.004_bb0160","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.8501","article-title":"Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II\/III non-small cell lung cancer (NSCLC): interim event-free survival (EFS) analysis of the phase III Neotorch study","volume":"41","author":"Lu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.04.004_bb0165","doi-asserted-by":"crossref","unstructured":"Cascone, T. et al. CheckMate 77T: phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II-IIIb NSCLC. Ann. Oncol. 34(S2), S1295.","DOI":"10.1016\/j.annonc.2023.10.050"},{"key":"10.1016\/j.trecan.2024.04.004_bb0170","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41591-023-02660-6","article-title":"Association between pathologic response and survival after neoadjuvant therapy in lung cancer","volume":"30","author":"Deutsch","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2024.04.004_bb0175","series-title":"Assessing the Use of ctDNA as an Early Endpoint in Early-stage Disease","author":"Friends of Cancer Research","year":"2021"},{"key":"10.1016\/j.trecan.2024.04.004_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.561598","article-title":"Circulating tumor DNA as a prognostic biomarker in localized non-small cell lung cancer","volume":"10","author":"Peng","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.trecan.2024.04.004_bb0185","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2024.04.004_bb0190","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.annonc.2022.02.007","article-title":"Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer","volume":"33","author":"Gale","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2024.04.004_bb0195","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1158\/2159-8290.CD-21-1486","article-title":"Longitudinal undetectable molecular residual disease defines potentially cured population in localized non-small cell lung cancer","volume":"12","author":"Zhang","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2024.04.004_bb0200","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1470-2045(06)70804-X","article-title":"Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial","volume":"7","author":"Douillard","year":"2006","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2024.04.004_bb0205","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1093\/annonc\/mdu442","article-title":"Adjuvant cisplatin-based chemotherapy in nonsmall-cell lung cancer: new insights into the effect on failure type via a multistate approach","volume":"25","author":"Rotolo","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2024.04.004_bb0210","doi-asserted-by":"crossref","first-page":"S1177","DOI":"10.1016\/j.annonc.2020.08.2279","article-title":"LBA1. Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): central nervous system (CNS) disease recurrence","volume":"31","author":"Tsuboi","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2024.04.004_bb0215","doi-asserted-by":"crossref","first-page":"S1295","DOI":"10.1016\/j.annonc.2023.10.051","article-title":"LBA2. ALINA: efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC)","volume":"34","author":"Solomon","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2024.04.004_bb0220","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2024.04.004_bb0225","doi-asserted-by":"crossref","first-page":"S1374","DOI":"10.1016\/j.annonc.2021.10.018","article-title":"2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC","volume":"32","author":"Zhou","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2024.04.004_bb0230","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2024.04.004_bb0235","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2024.04.004_bb0240","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1158\/1538-7445.AM2023-3375","article-title":"Ultrasensitive ctDNA minimal residual disease monitoring in early NSCLC with PhasED-Seq (Abstract 3395)","volume":"83","author":"Isbell","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2024.04.004_bb0245","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1158\/1538-7445.AM2024-986","article-title":"Mathematical modeling of ctDNA dynamics to predict utility of ultrasensitive MRD assays in early stage non-small cell lung cancer (NSCLC)","volume":"84","author":"Goldstein","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2024.04.004_bb0250","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.trecan.2024.04.004_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtcvs.2024.01.017","article-title":"Early real-world experience monitoring circulating tumor DNA in resected early-stage non-small cell lung cancer","author":"Martin","year":"2024","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.trecan.2024.04.004_bb0260","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1158\/1078-0432.CCR-22-1749","article-title":"A large-scale prospective concordance study of plasma- and tissue-based next-generation targeted sequencing for advanced non-small cell lung cancer (LC-SCRUM-Liquid)","volume":"29","author":"Sugimoto","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2024.04.004_bb0265","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2024.04.004_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00191","article-title":"Orthogonal comparison of four plasma NGS tests with tumor suggests technical factors are a major source of assay discordance","volume":"3","author":"Stetson","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.trecan.2024.04.004_bb0275","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jmoldx.2016.05.007","article-title":"The spectrum of clinical utilities in molecular pathology testing procedures for inherited conditions and cancer: a report of the Association for Molecular Pathology","volume":"18","author":"Joseph","year":"2016","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.trecan.2024.04.004_bb0280","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2217\/fon-2022-0868","article-title":"IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery","volume":"19","author":"Jackson-Spence","year":"2023","journal-title":"Future Oncol."},{"key":"10.1016\/j.trecan.2024.04.004_bb0285","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2024.04.004_bb0290","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40273-023-01292-5","article-title":"Health economic evidence and modeling challenges for liquid biopsy assays in cancer management: a systematic literature review","volume":"41","author":"Fagery","year":"2023","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.trecan.2024.04.004_bb0295","doi-asserted-by":"crossref","first-page":"S1373","DOI":"10.1016\/j.annonc.2021.10.017","article-title":"1O. Dynamic circulating tumour DNA (ctDNA) response to neoadjuvant (NA) atezolizumab (atezo) and surgery (surg) and association with outcomes in patients (pts) with NSCLC","volume":"32","author":"Kris","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2024.04.004_bb0300","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jtho.2022.09.005","article-title":"Stage shift improves lung cancer survival: real-world evidence","volume":"18","author":"Yang","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.trecan.2024.04.004_bb0305","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1097\/JTO.0000000000000320","article-title":"Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters","volume":"9","author":"Peters","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.trecan.2024.04.004_bb0310","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.chest.2018.10.020","article-title":"The accuracy of clinical staging of stage I-IIIa non-small cell lung cancer: an analysis based on individual participant data","volume":"155","author":"Navani","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.trecan.2024.04.004_bb0315","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N. Engl. J. Med."}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240580332400089X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240580332400089X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T21:54:09Z","timestamp":1720562049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240580332400089X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":63,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S240580332400089X"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2024.04.004","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2024.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}